Krsnaa Diagnostics has reported a robust financial performance for Q3 2024, achieving record net sales of Rs 186.34 crore and a 50.2% increase in profit before tax (PBT) to Rs 20.81 crore. The company’s operating profit margin improved to 26.51%, reflecting enhanced efficiency, although interest costs surged by 107.52%, highlighting a need for attention on borrowings. With positive trends in profitability and earnings, Krsnaa Diagnostics presents a compelling investment opportunity in the healthcare sector.
